Another extreme oversold small bio cap. Arca Biopharma Inc (NASDAQ:ABIO) touched a new 52 week low last week and closed at $2.36 a share on Friday. I think now is the time to start trying to catch this knife. Alone this company has more cash ($4 per share) than current market capitalization. Cash and cash equivalents were $58.3 million as of September 30, 2021, and they believe that its current cash and cash equivalents will be sufficient to fund its operations through 2022. Furthermore, the stock could get a boost from the current increase of the COVID cases worldwide, especially in Europe. According to CEO Dr. Michael Bristow, with rNAPc2’s combination of anticoagulant, anti-inflammatory and potential antiviral properties, he believes it has the potential to be effective in addressing COVID-19 impacts in hospitalized patients. The international Phase 2b clinical trial is nearing completion and they look forward to sharing its results in the first quarter. I have been accumulating shares again.